Email updates

Keep up to date with the latest news and content from Journal of Molecular Signaling and BioMed Central.

Open Access Research article

EGFR/Met association regulates EGFR TKI resistance in breast cancer

Kelly L Mueller12, Zeng-Quan Yang13, Ramsi Haddad1, Stephen P Ethier13 and Julie L Boerner12*

Author Affiliations

1 Karmanos Cancer Institute at Wayne State University, John R. St, Detroit, MI 48201, USA

2 Department of Pharmacology at Wayne State University, E. Canfield, Detroit, MI 48201, USA

3 Department of Pathology at Wayne State University, Detroit, MI, 48201, USA

For all author emails, please log on.

Journal of Molecular Signaling 2010, 5:8  doi:10.1186/1750-2187-5-8

Published: 12 July 2010


Breast cancers show a lack of response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), despite 30% of tumors expressing EGFR. The mechanism of this resistance is unknown; however, we have recently shown that Met kinase activity compensates for loss of EGFR kinase activity in cell culture models. Met has been implicated in the pathogenesis of breast tumors and therefore may cooperate with EGFR for tumor growth. Here we have found that EGFR phosphorylation and cell proliferation is in part regulated by Met expression. In addition, we found that Met constitutive phosphorylation occurred independent of the Met ligand hepatocyte growth factor (HGF). Ligand-independent Met phosphorylation is mediated by Met amplification, mutation, or overexpression and by Met interaction with other cell surface molecules. In SUM229 breast cancer cells, we found that Met was not amplified or mutated, however it was overexpressed. Met overexpression did not directly correlate with ligand-independent Met phosphorylation as the SUM229 cell line was the only Met expressing breast cancer line with constitutive Met phosphorylation. Interestingly, Met expression did correlate with EGFR expression and we identified an EGFR/Met complex via co-immunoprecipitation. However, we only observed Met constitutive phosphorylation when c-Src also was part of this complex. Ligand-independent phosphorylation of Met was decreased by down regulating EGFR expression or by inhibiting c-Src kinase activity. Lastly, inhibiting EGFR and Met kinase activities resulted in a synergistic decrease in cell proliferation, supporting the idea that EGFR and Met functionally, as well as physically interact in breast cancer cells to regulate response to EGFR inhibitors.